ライフサイエンスコーパス: polymorphic ventricular tachycardia

1 rhythmia and sudden death (catecholaminergic polymorphic ventricular tachycardia).

2 romes (e.g., flecainide in catecholaminergic polymorphic ventricular tachycardia).

3 te as [corrected] "shifting" foci resembling polymorphic ventricular tachycardia.

4 ons and extrasystolic Ca2+ waves, leading to polymorphic ventricular tachycardia.

5 dentified in patients with catecholaminergic polymorphic ventricular tachycardia.

6 nged QT intervals, QT interval lability, and polymorphic ventricular tachycardia.

7 und to underlie the mechanism of spontaneous polymorphic ventricular tachycardia.

8 gthy delay to diagnosis in catecholaminergic polymorphic ventricular tachycardia.

9 outcomes in children with catecholaminergic polymorphic ventricular tachycardia.

10 ong-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia.

11 tic denervation in LQTS or catecholaminergic polymorphic ventricular tachycardia.

12 , cardiac hypertrophy, and catecholaminergic polymorphic ventricular tachycardia.

13 as the long-QT syndrome or catecholaminergic polymorphic ventricular tachycardia.

14 lve RyRs, such as malignant hyperthermia and polymorphic ventricular tachycardia.

15 iac arrhythmias, including catecholaminergic polymorphic ventricular tachycardia.

16 rome, Brugada Syndrome, or Catecholaminergic Polymorphic Ventricular Tachycardia.

17 rhythmogenic mechanism for catecholaminergic polymorphic ventricular tachycardia.

18 other raised suspicion for catecholaminergic polymorphic ventricular tachycardia.

19 n that was consistent with catecholaminergic polymorphic ventricular tachycardia.

20 cytes, and correlated with catecholaminergic polymorphic ventricular tachycardia.

21 mphetamine, marijuana, and catecholaminergic polymorphic ventricular tachycardia.

22 in an established model of catecholaminergic polymorphic ventricular tachycardia.

23 ome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia.

24 n CASQ2 has been linked to catecholaminergic polymorphic ventricular tachycardia.

25 Complications other than AV block included polymorphic ventricular tachycardia 10 to 24 h after the

26 syndrome, 3/18 (17%); and catecholaminergic polymorphic ventricular tachycardia, 2/18 (11%).

27 ted patients were sustained and nonsustained polymorphic ventricular tachycardia (3.6%).

28 e, 9; Brugada syndrome, 8; catecholaminergic polymorphic ventricular tachycardia, 3; short QT syndrom

29 ng Long-QT syndrome (13%), catecholaminergic polymorphic ventricular tachycardia (4%), arrhythmogenic

30 disease factors (18; 38%; catecholaminergic polymorphic ventricular tachycardia [6], near-drowning [

31 CASQ2) genes are linked to catecholaminergic polymorphic ventricular tachycardia, a life-threatening

32 have been associated with catecholaminergic polymorphic ventricular tachycardia and a form of arrhyt

33 mural reentry over transmural reentry during polymorphic ventricular tachycardia and fibrillation.

34 cardiac diseases, such as catecholaminergic polymorphic ventricular tachycardia and heart failure (H

35 tiologies established were catecholaminergic polymorphic ventricular tachycardia and long QT syndrome

36 ed the predominant role of catecholaminergic polymorphic ventricular tachycardia and long QT syndrome

37 iac arrest secondary to multiple episodes of polymorphic ventricular tachycardia and ventricular fibr

38 ontaneous ventricular arrhythmias, including polymorphic ventricular tachycardia and ventricular fibr

39 r in which mutation carriers are at risk for polymorphic ventricular tachycardia and/or sudden cardia

40 logists: long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrom

41 ventricular fibrillation, catecholaminergic polymorphic ventricular tachycardia, and risk of sudden

42 ome; 4 long-QT syndrome; 1 catecholaminergic polymorphic ventricular tachycardia; and 2 cardiomyopath

43 ns in long QT syndrome and catecholaminergic polymorphic ventricular tachycardia-associated genes in

44 roperties of wild-type and catecholaminergic polymorphic ventricular tachycardia-associated RyR2(R449

45 A polymorphic ventricular tachycardia closely resembling T

46 thmia syndromes, including catecholaminergic polymorphic ventricular tachycardia, congenital long QT

47 ecently been identified in catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmo

48 mutations associated with catecholaminergic polymorphic ventricular tachycardia (CPVT) and atrial fi

49 cause arrhythmias such as catecholaminergic polymorphic ventricular tachycardia (CPVT) and long QT s

50 ong QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) are electric

51 mutations associated with catecholaminergic polymorphic ventricular tachycardia (CPVT) are postulate

52 Catecholaminergic polymorphic ventricular tachycardia (CPVT) causes sudden

53 ation R33Q leads to lethal catecholaminergic polymorphic ventricular tachycardia (CPVT) implies a cru

54 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a conditio

55 Catecholamine-induced polymorphic ventricular tachycardia (CPVT) is a familial

56 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial

57 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic

58 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a lethal,

59 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentia

60 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentia

61 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherit

62 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherit

63 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by

64 efficacy of flecainide for catecholaminergic polymorphic ventricular tachycardia (CPVT) is unclear.

65 rgent clinical features of catecholaminergic polymorphic ventricular tachycardia (CPVT) or long QT sy

66 ong-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) represent tre

67 sms of arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia (CPVT) require spont

68 gene (RYR2) cause dominant catecholaminergic polymorphic ventricular tachycardia (CPVT), a leading ca

69 In catecholaminergic polymorphic ventricular tachycardia (CPVT), cardiac Purk

70 These arrhythmias include catecholaminergic polymorphic ventricular tachycardia (CPVT), certain case

71 of concealed LQT1, namely catecholaminergic polymorphic ventricular tachycardia (CPVT), may also und

72 c Ca(2+) release events in catecholaminergic polymorphic ventricular tachycardia (CPVT), yet evidence

73 at are associated with catecholamine-induced polymorphic ventricular tachycardia (CPVT).

74 e been associated with catecholamine-induced polymorphic ventricular tachycardia (CPVT).

75 ms of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT).

76 rial fibrillation (AF) and catecholaminergic polymorphic ventricular tachycardia (CPVT).

77 sudden death-predisposing catecholaminergic polymorphic ventricular tachycardia (CPVT).

78 em cells (hiPSCs) model of catecholaminergic polymorphic ventricular tachycardia (CPVT).

79 lar tachycardia in humans [catecholaminergic polymorphic ventricular tachycardia (CPVT)].

80 hythmias (in patients with catecholaminergic polymorphic ventricular tachycardia [CPVT]) reduced the

81 uced sudden cardiac death (catecholaminergic polymorphic ventricular tachycardia [CPVT]).

82 cise-induced sudden death (catecholaminergic polymorphic ventricular tachycardia [CPVT]).

83 tions in RYR2 cause type 1 catecholaminergic polymorphic ventricular tachycardia (CPVT1), a cardiac c

84 olecular mechanism for the catecholaminergic polymorphic ventricular tachycardia (CPVT2) mutation, K2

85 Foremost are those with catecholaminergic polymorphic ventricular tachycardia due to abnormalities

86 tilide-treated patients, 15 (8.3%) developed polymorphic ventricular tachycardia during or soon after

87 In catecholaminergic polymorphic ventricular tachycardia, excess mortality wa

88 long QT syndrome (1/2) and catecholaminergic polymorphic ventricular tachycardia families (1/2) who w

89 Familial polymorphic ventricular tachycardia (FPVT) is characteri

90 ase dysfunction underlying catecholaminergic polymorphic ventricular tachycardia has only been invest

91 ome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia have been associated

92 1.65, p < 0.0001), ventricular fibrillation/polymorphic ventricular tachycardia (HR: 2.10, p < 0.000

93 to study long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, hypertrophic cardio

94 transmural repolarization in the genesis of polymorphic ventricular tachycardia in a canine model of

95 in leaky channels and cause exercise induced polymorphic ventricular tachycardia in humans [catechola

96 . high sympathetic tone, are associated with polymorphic ventricular tachycardia in LQTS patients.

97 nts manifest ventricular premature beats and polymorphic ventricular tachycardia in response to exerc

98 Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in RyR2(R4496C+/-) m

99 monstrate that azithromycin can cause rapid, polymorphic ventricular tachycardia in the absence of QT

100 The potential for producing polymorphic ventricular tachycardia in the rabbit model

101 Catecholaminergic polymorphic ventricular tachycardia is a form of exercis

102 Catecholaminergic polymorphic ventricular tachycardia is a heritable arrhy

103 Catecholaminergic polymorphic ventricular tachycardia is an inherited dise

104 Catecholaminergic polymorphic ventricular tachycardia is an uncommon, pote

105 The recessive form of catecholaminergic polymorphic ventricular tachycardia is caused by mutatio

106 Catecholaminergic polymorphic ventricular tachycardia is characterized by

107 Catecholaminergic polymorphic ventricular tachycardia is directly linked t

108 Familial polymorphic ventricular tachycardia is due to a defect i

109 in-2 gene; this variant of catecholaminergic polymorphic ventricular tachycardia is less well charact

110 CASQ2 protein carrying the catecholaminergic polymorphic ventricular tachycardia-linked mutation D307

111 dling in mice carrying the catecholaminergic polymorphic ventricular tachycardia-linked mutation of r

112 terozygous mice carrying a catecholaminergic polymorphic ventricular tachycardia-linked RyR2 mutation

113 We have shown that catecholaminergic polymorphic ventricular tachycardia-linked RyR2 mutation

114 Patients with catecholaminergic polymorphic ventricular tachycardia manifest sinoatrial

115 ythmias in CASQ2-defective catecholaminergic polymorphic ventricular tachycardia mice.

116 previously identified in a catecholaminergic polymorphic ventricular tachycardia model.

117 ic contractions (DCs) in a catecholaminergic polymorphic ventricular tachycardia mouse model with a m

118 ), supraventricular tachycardia (n = 1), and polymorphic ventricular tachycardia (n = 1).

119 thmogenic disease included catecholaminergic polymorphic ventricular tachycardia (n=13), Jervell and

120 ients with LQTS (N=40) and catecholaminergic polymorphic ventricular tachycardia (N=7) underwent vide

121 Sustained polymorphic ventricular tachycardia occurred in 2 of the

122 polarization that could potentially initiate polymorphic ventricular tachycardia or fibrillation.

123 entricular tachycardia, ventricular flutter, polymorphic ventricular tachycardia, or ventricular fibr

124 us to what was observed in catecholaminergic polymorphic ventricular tachycardia patients after exerc

125 rospective cohort study of catecholaminergic polymorphic ventricular tachycardia patients diagnosed b

126 to the SAN dysfunction in catecholaminergic polymorphic ventricular tachycardia patients.

127 Polymorphic ventricular tachycardia (PMVT) has been repo

128 ation play a critical role in the genesis of polymorphic ventricular tachycardia (PVT) when QT interv

129 monomorphic ventricular tachycardia (MVT) or polymorphic ventricular tachycardia (PVT)/ventricular fi

130 with long QT syndrome and catecholaminergic polymorphic ventricular tachycardia received routine bet

131 nd to be a protocol violation, had sustained polymorphic ventricular tachycardia requiring direct cur

132 NQ1, KCNH2, and SCN5A) and catecholaminergic polymorphic ventricular tachycardia-susceptibility gene

133 and long QT, Brugada, and catecholaminergic polymorphic ventricular tachycardia syndromes) should al

134 gment elevation in V1 through V3 and a rapid polymorphic ventricular tachycardia that can degenerate

135 diac death cases linked to catecholaminergic polymorphic ventricular tachycardia that feature lethal

136 tions in 2 genes linked to catecholaminergic polymorphic ventricular tachycardia, the first located i

137 rval prolongation, and the potentially fatal polymorphic ventricular tachycardia torsade de pointes,

138 tening cardiac arrhythmias, specifically the polymorphic ventricular tachycardia torsades de pointes.

139 ion of the cardiac action potential leads to polymorphic ventricular tachycardia (torsades de pointes

140 rdiogram and the morphologically distinctive polymorphic ventricular tachycardia ('torsades de pointe

141 Catecholaminergic polymorphic ventricular tachycardia type 2 (CPVT2) resul

142 tachycardia, n = 44; pause/asystole, n = 36; polymorphic ventricular tachycardia/ventricular fibrilla

143 ale and 1 of 2 female preparations developed polymorphic ventricular tachycardia/ventricular fibrilla

144 function and an increased incidence of rapid polymorphic ventricular tachycardia (VT) and sudden card

145 rapy for the management of catecholaminergic polymorphic ventricular tachycardia (VT) in young patien

146 Catecholaminergic polymorphic ventricular tachycardia (VT) is a lethal fam

147 Polymorphic ventricular tachycardia (VT) is rare and gen

148 %) died suddenly, one with Holter-documented polymorphic ventricular tachycardia (VT).

149 uding long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia (VT).

150 specific genetic test for catecholaminergic polymorphic ventricular tachycardia was sent.

151 Polymorphic ventricular tachycardia was the most serious

152 All patients with sustained polymorphic ventricular tachycardia were successfully tr

153 icular cardiomyopathy, and catecholaminergic polymorphic ventricular tachycardia were the most common

154 Spontaneous and stimulation-induced polymorphic ventricular tachycardia with characteristics

155 genetic arrhythmia syndrome characterized by polymorphic ventricular tachycardia with physical or emo

156 n, and demonstrated facilitated induction of polymorphic ventricular tachycardia, without antecedent